96 related articles for article (PubMed ID: 11804341)
1. A divalent recombinant immunotoxin formed by a disulfide bond between the extension peptide chains.
Park JH; Kwon HW; Chung HK; Kim IH; Ahn K; Choi EJ; Pastan I; Choe M
Mol Cells; 2001 Dec; 12(3):398-402. PubMed ID: 11804341
[TBL] [Abstract][Full Text] [Related]
2. Disulfide bond bridged divalent antibody-toxin, (Fab-PE38fl)2, with the toxin PE38 fused to the light chain.
Won J; Choe M
J Microbiol Biotechnol; 2008 Aug; 18(8):1475-81. PubMed ID: 18756111
[TBL] [Abstract][Full Text] [Related]
3. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
Bera TK; Pastan I
Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
[TBL] [Abstract][Full Text] [Related]
4. [Construction and activity analysis of a recombinant immunotoxin composed of PE38 and a disulfide stable single-chain antibody].
Wang JL; Zheng YL; Wang BL; Guo AG; Ma R; Jiang YQ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Jan; 22(1):74-7. PubMed ID: 16388751
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
[TBL] [Abstract][Full Text] [Related]
6. Enhanced formation of disulfide-bridged dimer (Fab-PE38)2 utilizing repeats of the Fab binding domain of protein G.
Lee Y; Park J; Kweon S; Choe M
J Biol Chem; 2010 Feb; 285(8):5127-31. PubMed ID: 20022943
[TBL] [Abstract][Full Text] [Related]
7. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
Kreitman RJ; Margulies I; Stetler-Stevenson M; Wang QC; FitzGerald DJ; Pastan I
Clin Cancer Res; 2000 Apr; 6(4):1476-87. PubMed ID: 10778980
[TBL] [Abstract][Full Text] [Related]
8. Higher cytotoxicity of divalent antibody-toxins than monovalent antibody-toxins.
Won J; Nam P; Lee Y; Choe M
Biochem Biophys Res Commun; 2009 Apr; 382(1):15-20. PubMed ID: 19245794
[TBL] [Abstract][Full Text] [Related]
9. B3(Fab)-PE38M: a recombinant immunotoxin in which a mutant form of Pseudomonas exotoxin is fused to the Fab fragment of monoclonal antibody B3.
Choe M; Webber KO; Pastan I
Cancer Res; 1994 Jul; 54(13):3460-7. PubMed ID: 8012967
[TBL] [Abstract][Full Text] [Related]
10. Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.
Salvatore G; Beers R; Margulies I; Kreitman RJ; Pastan I
Clin Cancer Res; 2002 Apr; 8(4):995-1002. PubMed ID: 11948105
[TBL] [Abstract][Full Text] [Related]
11. Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3.
Benhar I; Pastan I
J Biol Chem; 1995 Oct; 270(40):23373-80. PubMed ID: 7559495
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2.
Bera TK; Viner J; Brinkmann E; Pastan I
Cancer Res; 1999 Aug; 59(16):4018-22. PubMed ID: 10463601
[TBL] [Abstract][Full Text] [Related]
13. [Construction and prokaryotic expression of a recombinant immunotoxin fused with mouse interleukin 18 and truncated Pseudomonas exotoxin].
Li H; Li MY; Jiang ZH; Lü ML; Zhang L
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):753-6. PubMed ID: 15573745
[TBL] [Abstract][Full Text] [Related]
14. Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins.
Hexham JM; Dudas D; Hugo R; Thompson J; King V; Dowling C; Neville DM; Digan ME; Lake P
Mol Immunol; 2001 Sep; 38(5):397-408. PubMed ID: 11684296
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of Antiosteosarcoma Recombinant Immunotoxins Composed of TP-3 Fv Fragments and a Truncated Pseudomonas Exotoxin A.
Onda M; Olafsen T; Tsutsumi Y; Bruland ØS ØS; Pastan I
J Immunother (1991); 2001 Mar; 24(2):144-150. PubMed ID: 11449071
[TBL] [Abstract][Full Text] [Related]
16. [Molecular design and construction of IL6D24-PE40KDEL, a novel recombinant interleukin6-pseudomonas exotoxin fusion protein, having targeted cytotoxicity for leukemias expressing interleukin6 receptors].
Zheng LY; Xi YZ; Kong FH; Cui JW; Liang F; Liu N; Sun YY; Guo SQ
Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(14):1246-50. PubMed ID: 12930640
[TBL] [Abstract][Full Text] [Related]
17. Rapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3(Fv)-PE38.
Benhar I; Padlan EA; Jung SH; Lee B; Pastan I
Proc Natl Acad Sci U S A; 1994 Dec; 91(25):12051-5. PubMed ID: 7991583
[TBL] [Abstract][Full Text] [Related]
18. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
[TBL] [Abstract][Full Text] [Related]
19. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
20. Administration of disulfide-stabilized Fv-immunotoxins B1(dsFv)-PE38 and B3(dsFv)-PE38 by continuous infusion increases their efficacy in curing large tumor xenografts in nude mice.
Benhar I; Reiter Y; Pai LH; Pastan I
Int J Cancer; 1995 Jul; 62(3):351-5. PubMed ID: 7628878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]